- CA 125 in the early detection of metastatic breast cancer
- Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab
- Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Advan
- Study Findings Released Showing Ginger Provides Significant Reduction of Chemotherapy
- Secondary malignancies developing during metastatic breast cancer treatment
- Hormonal changes with anastrozole treatment in breast cancer
- Detection of locally advanced breast cancer in the I-SPY TRIAL
- Ki-67 in benign breast tissue from premenopausal women treated with a flaxseed deriva
- A study of lavender and tea tree oils on postmenopausal FSH levels and hot flash seve
- Effect of simvastatin on the pharmacokinetics of anastrozole
- Evaluation of the effect of screening on the detection of good and poor prognosis bc
- Factors leading to the decision for contralateral prophylactic mastectomy
- Neuroprotective effect of SSRI among 781 cancer patients receiving chemotherapy
- Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies
- Changes in body composition in women with breast cancer on aromatase inhibitors
- Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 bl
- ASCO Releases Updated Guideline on Breast Cancer Risk Reduction
- Studies Shed Light on Critical Challenges in Cancer Research and Care
- Studies Report Progress Against Breast and Gynecologic Cancers
- ASCO: No Survival Loss with Partial-Breast Irradiation
- ASCO: Action Needed in Early Breast CA with Isolated Cells in Lymph Nodes
- Sexual dysfunction in women with breast cancer: Prevalence and severity
- The epidemiology of herpes zoster in patients with invasive cancer
- Cognitive functioning in breast cancer patients during and following chemotherapy
- Scalp cooler efficacy to reduce anthracycline-induced alopecia and its QOL impact
- Is the maximal tolerated dose still the best primary endpoint?
- Ixabepilone and lapatinib for HER2-positive advanced breast cancer
- New Class of Drugs in Early Trials Offers Hope for Breast Cancer
- Adoptive T-cell therapy in Her2+ MBC
- Persistent immunity and survival after immunization with a HER2/neu (HER2) vaccine
- A DNA plasmid based vaccine encoding the HER2/neu
- Metronomic use of zoledronic acid on antitumor and antiosteoclastic effects in MBC
- Functional imaging of neoadjuvant chemo response
- HSP90 inhibition in HER2-positive breast cancer cells
- Best of ASCO events around the world
- Antitumor effects of OSU-HDAC42 in HER-2-positive breast cancer
- Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy
- Development of combination chemotherapy regimens: What is the yield of phase II Trial
- Association between lung cancer survival and pessimistic explanatory style
- Interpreting out-of-pocket expenditures for cancer patients
- Cost implications of delayed radiotherapy for early stage breast cancer
- MBC treated by chemotherapy: Trends in survival and costs
- Impact of brain metastases on health care costs (specifically Her2+)
- Clinical benefit in oncology trials: Is this a patient-centered or tumor-centered end
- What price for a year of life? A survey of U.S. and Canadian oncologists
- Weight changes in breast cancer survivors who received adjuvant antiestrogen therapy
- Oncology nurses' views of oncologists' prognosis-related communication (PRC)
- Sniffing out cancer from real breath samples
- Non-breast cancer mortality after a breast cancer diagnosis
- Distribution and determinants of patient satisfaction in oncology
- Understanding among medical oncologists of the true monetary cost of therapy
- Recommendation of adjuvant chemotherapy and trastuzumab in older adults
- Trastuzumab in the elderly: Is it age or cardiovascular risk profile that really matt
- Associations between coping methods and use of intensive life-prolonging care
- End-of-life care: Empowering cancer patients with information and choices
- Validation of a scoring system to improve life expectancy prediction in advanced canc
- Complementary and alternative medicine: What do oncology healthcare providers think?
- Sudden onset fatigue (SOF) in patients with breast cancer: Characteristics and sympto
- Prognostic significance of the "surprise" question in cancer patients
- Is a diagnosis of invasive bc an effective motivational factor for lifestye change?
- The effect of tai chi chuan on bone remodeling and cytokines among bc survivors
- The effect and safety of Clino-san on vaginal symptoms in breast cancer survivors
- Determining issues of importance for patients with breast cancer
- Phase III randomized anastrozole exercise (RAE) trial: First planned interim analysis
- Scintigraphic evaluation of mandibular bone turnover inhibition by bisphosphonates
- Randomized clinical trial of medical qigong on QOL in cancer patients
- Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in bc
- Vitamin D levels during and after high-dose vitamin D supplementation
- The era of oral drugs in oncology: What do patients think about their efectiveness?
- Distal or proximal venous port device insertion: Results of a prospective randomized
- Vitamins B6 and B12 supplementation to prevent chemotherapy-induced neuropathy
- Prospective evaluation of oral mucositis in chemotherapy patients
- Fever in cancer patients as a cause of attendance in emergency room
- Review of toxicities of erythropoietins
- PIK3CA mutation analysis in recurrent breast cancer
- Genome-wide scan in women with bc to identify variants associated with recurrence
- The association of cancer and allergic symptoms among female adult
- Risk of acute renal failure among breast cancer patients
- Discovery of a new phospho-HER2+/FISH- molecular subtype
- Early assessment of response to aromatase inhibitor (AI) therapy
- Combining multigene profiling of molecular subtypes with the 70-gene profile
- Prognostic value of the genomic grade index to Ki-67 in bc patients
- Clinical relevance of small tumor size (pT1a-b) for patients with HER2+ node neg bc
- Incidence of low-level HER2 gene amplification and chromosome 17 polysomy
- HER2 FISH ratio cut-points and pathologic complete response
- Pattern of relapse and risk of second malignancies in molecular subtypes of early bc
- Does hormone receptor positivity affect prognosis in Her2+ bc?
- Relationship between LVI and prognostic markers in different subtypes of bc
- Predictive and prognostic functions of microtubule-associated protein-tau and topoiso
- KI67 in breast cancer: Correlation between proliferation cellular and other prognosti
- GRB7 and HER2 protein overexpression and breast cancer outcome
- Impact of molecular subtype on presenting characteristics of T1a,b tumors
- Methylation profile of human breast cancer: possible biomarker for detection of CTCs
- Effect of trastuzumab on the reduction of hormone receptor expression by chemotherapy
- Mammary adipose tissue and cancer cell growth: role of adipose tissue
- Incomplete surgical resection of DCIS results in activation of HER-2 in residual bc
- Interactions of bc cells w/microenvironment of the human bone marrow
- role of estrogen receptor β expression as a predictive and/or prognostic factor in bc
- Correlation of quantitative total HER2 expression and HER2 homodimers in FinHer study
- Impact of biopsy cavities in breast cancer samples on recurrence risk
- Evaluation of the nuclear receptor FXR to link metabolism with breast cancer
- Relationship of BMI, meno status, HRT & BC risk
- The association between the use of statin and breast cancer recurrence
- Clinical significance of three new phenotypes of bc identified by cell cycle protein
- BSGI compared to breast MRI
- MBC patients with very high Her2+ and herceptin resistance
- Biopsy cavities in bc specimens: Impact on gene expression profiles and recur. Score
- Does estrogen receptor expression vary with fixation time?
- Comparison of bc recurrence risk & cardiovascular disease risk among postmeno bc surv
- Effect of sexual dysfunction on quality of life in women with breast cancer
- Advocate involvement in NCCN Breast Cancer Guidelines: A model of advocate/researcher
- Breast cancer survivor care: Duke provider survey
- Clinical implications of the molecular relationship between HER2 and BRCA1
- Microarray of breast cancer stem cells and the study of gene regulatory networks
- Insulin resistance and early weight gain in women treated for newly-diagnosed bc
- Comparison of perceptions in bc patients in acute & extended survival phases
- Impact of patients' concern for fertility on decision making of adjuvant Tx
- Challenges in breast cancer survivorship for musicians
- Radio frequency ablation (RFA) of hepatic metastases in breast cancer patients
- Sexual problems after breast cancer diagnosis
- Comparative study of estrogen vaginal ring and estrogen vaginal tablet for pts on AIs
- Benefits of trastuzumab-based therapy for women with small, node-negative, HER2+ bc
- ASCO San Francisco Breast Cancer Meeting
- ASCO SF Breast Cancer meeting
- At the Breast Cancer Symposium 2009
- Does anyone have access to these 2009 ASCO PPT?
- AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Program and poster titles for 2009 SABCS on web site
- Bone Health symposium (for health care professionals)
- 2009 sabcs
- Treatment-Emergent Symptoms and the Risk of Breast Cancer Recurrence in AI Trial
- Genomic study on arthralgia symptoms in AI patients - seeking a genomic basis
- Alcohol and Breast Cancer Survival in a Prospective Cohort Study
- Effect of Obesity on Prognosis after Early Breast Cancer
- Adjusting for Selective Crossover in Analyses of Letrozole Vs Tamoxifen Trial
- Use of Bisphosphonates and Risk of Postmenopausal Breast Cancer
- Limited Clinical Utility of Prognostic Gene Expression Profiles in Grade 3 Node-Neg B
- Prognostic Signature Based on the Expression of Insulin-Related Genes in early BC
- Preventive Effects of Lapatinib on ER+ and MMTV-Neu/P53 KO ER- Mammary Cancers
- Effect of Body Mass Index on Recurrence in Hormone Receptor Positive Early BC
- Deleterious Effect of Chemotherapy on Measures of Insulin Resistance
- Burden of Sexual Dysfunction in Women with Breast Cancer
- Neoadjuvant Herceptin + Chemo = eradication of lymph node mets in 74% of pts
- Pathologic Complete Response and Survival after Trastuzumab-Based Neoadjuvant Therapy
- Prospective Study of Ice Gel Pack as Alternative for Prevention of Skin & Nail Toxici
- DNA Oxidative Damage and Repair profiles differ with stage of treatment
- Metformin Enhances Trastuzumab Efficacy and Overcomes Resistance in HER2 Type BC cell
- Subtype Dependent Alterations of the DNA Methylation Landscape in Breast Cancer
- Epigenetics Differences between Estrogen Receptor (ERS1) and Her2/Neu Status in BC
- Resident Macrophages Influence Stem Cell Activity in the Mammary Gland
- Distant Metastasis Free Survival in Breast Cancer Patients with Micrometastases
- Resistance to Endocrine Therapy in ER+ pts. is dependent on PK13 signaling
- Progesterone Receptor (PR) Promoter Methylation – Role as a Predictive and Prognostic
- The Role of CYP2D6 as a Predictor of Tamoxifen Resistance in ER+/HER2+ Breast Cancer
- Drug sensitivity prediction model using primary tumor gene expression profiles
- Correlations between GREB1 Expression and Estrogen Receptor, HER2 Status in Human BC
- Poor Survival Outcomes in Elderly HER2 Positive Breast Cancer Patients
- Early Assessment of Proliferation by the Genomic Grade Index (GGI) Predicts Response
- The 76-Gene Signature Defines High-Risk Patients That Benefit from Adjuvant Tamoxifen
- Pleomorphic Calcifications, Tumor Markers, and Response to Therapy
- Prediction of Response to Paclitaxel by ChemoFx assay Correlates with Estrogen Recept
- Multiple Subtypes of HER-2/Neu-Positive Metastatic Breast Cancer
- Risk of Death Due to Breast Cancer in Women Treated with SSRIs
- Breast Cancer Patients Are 30% More Likely To Develop Arterial Thromboembolic Events
- Myelodysplastic Syndrome and Acute Myeloid Leukemia Incidence Following Primary BC tx
- The Quality of Decisions about Adjuvant Chemotherapy for Early Stage Breast Cancer
- Behaviour of CETC during Adjuvant Trastuzumab Treatment in Patients with Her2+ BC
- Paclitaxel related neuropathy in pts who did not receive Herceptin = improved outcome
- Aberrations of HER2 and TOP2A Genes in Breast Cancer
- Xtalk between ER Receptor alpha 36 & HER2 Promotes Tumor Cell Survival
- mTORC1 Activity Contributes to the Mcl-1 Dependence of HER2 Amplified BC Cells
- Does Primary Systemic Therapy Erradicate Disseminated and Circulating Tumor Cells?
- ER & PR Expression Profile of CTCs in MBC pts in Comparison to the Primary Tumor
- Amplification and Activation of HER2 in CTCs in MBC pts
- Bone Marrow Micrometastasis as Correlated to Other Prognostic Factors in BC
- Evaluation of CA 27.29 as Prognostic Marker in Primary Breast Cancer Patients
- Differences in Signaling pathways between normal and bc patients
- Correlation of Oncotype DX Recurrence Score with Cyclin D1 and ErbB2
- The Influence of Mode of Presentation on the Pattern of Recurrence in Early BC
- Incidence and Demographic and Tumor Characteristics of HER2+ Invasive BC
- Lapatinib Restores Endocrine Sensitivity in Selected Patients
- Curcumin Modulates Tamoxifen Response in Resistant Breast Cancer Cells
- ACE Inhibitors and Angiotensin Receptor Blockers May Reduce Breast Cancer Recurrence
- Metformin Inhibits Aromatase Expression in Primary Human Breast Adipose Stromal Cells
- Wound Fluid Induces Cancer Cell Growth: A Mechanism for Recurrence?
- Childbirth Following BC: An Evaluation of the 'Healthy Mothers' Excess Mortality Risk
- Long Term Persistent Alopecia after Adjuvant Chemotherapy for BC
- Single Injection Depot Progesterone Prior to Surgery and Survival in BC pts
- ER and HER2 Expression Are POSITIVELY Correlated in HER2 Non-Over Expressing BC
- Differential Signaling by HER Dimers & Response to Anti Her2 Therapy
- Different Mechanisms for Acquired Resistance to Trastuzumab and Lapatinib
- Testosterone Undecanoate Treatment Reduces Joint Morbidities Induced by Anastrozole
- Effects of Vaginal Estrogens on Serum Estradiol Levels in postmeno BC pts on AI/SERMs
- Prospective Evaluation of Neurotoxicity in BC Patients Treated w/Paclitaxel
- Baseline Endogenous Estradiol and the Association of Hormone Therapy with BC Risk
- Sex Hormones and Risk of Estrogen Receptor (ER)-Positive and ER-Negative BC
- Protective Effect of Estrogen (E2) and Increased Risk of E2 Plus Progestin on BC
- Prediction of Prognosis and Treatment Benefit by the Adjuvant! Web-Based Tool
- Polysomy of Chromosome 17 in Breast Cancer
- ER Status, Immune Module & Her2 BC Prognosis
- The Influence of HER2 Status on the Recurrence Pattern in ER+ BC
- A New Safer and More Effective Triphenylethylene Antiestrogen (SS1020)
- Effects of Adjuvant Anastrozole, Letrozole & Exemestane on Lipid Metabolism
- Testosterone Supplementation during Anastrozole Therapy in a Breast Explant Model
- Immune Competence in Breast Cancer Patients 6 Months Post Surgery & Adjuvant Therapy
- HER2-Associated Breast Cancer Signature Using a 3D Culture Model
- Relationships between Progesterone Receptor Isoforms and the HER Receptors
- Impact of Recording of Pre-Analytical Specimen Handling Conditions for ER & PR Testin
- Capturing Changes in the Brain Microenvironment during Initial Tumor Cell Invasion
- Vaginal Testosterone Cream vs. Estring for Vaginal Dryness or Libido
- Scalp Hypothermia Minimizes Alopecia in Non-Anthracycline Chemo
- Medical Ozone (O3) Oil or Gas Applications Heal Osteonecrosis of the Jaw
- How Important Is Cognition for Women with Breast Cancer?
- Combining HSP90 Inhibition with Standard Therapies for HER2 Positive Breast Cancer
- SABC: How to Pack a Room
- SASC: Choose Your Words Carefully
- Standard dose of Herceptin may be substandard for very high Her2+ pts
- Time Dependent Improvement in Survival for Women w/ Multiple Her2+ Brain Metastases
- Gastro & Cardio safety profiles of Neratinib
- Phase II Study of a HER-2/Neu Vaccine Given Concurrently with Trastuzumab
- Risk Factor Combinations for Estimating the Probability of BCRelated Lymphedema
- Estrogen Deprivation Results in Altered DNA Methylation Profile in Breast Cancer Cell
- Study on clinical outcomes in ER+ vs ER-, Her2+ patients
- Metabolic Syndrome in Breast Cancer
- Selective Effects of Glucose, Insulin and Leptin by Molecular Breast Cancer Subtype
- Antiproliferative Effect of Calcitriol Depends on Vitamin D Receptor Status
- Should Liver Metastases of Breast Cancer Be Biopsied To Improve Treatment Choice?
- Grade 3 Status Dominates Prognosis in Breast Cancer
- Relationship between Biomarkers of Inflammation & BC specific survival
- Heterogeneous Amplification of HER2 Is a Rare but Clinically Significant Event in IDC
- Prognostic Significance of Nodal and PgR Status on Early Relapse in Her2+ bc pre-Herc
- Weight Variation during Chemotherapy and Breast Cancer Prognostic
- ER+/PR+ Her2+ have longer DFS but similar overall survival to ER-/PR- Her2+
- Genetic Susceptibility as a Possible Risk Factor for Breast Cancer
- Incidence of & Predictive Factors for Recovery of Ovarian Function on Letrozole
- A 'Field Effect' in Breasts w/ cancer Results in an Altered Cell Expression Profile
- Genes Regulating the Progression of Human DCIS to Invasive Breast Cancer
- Outcomes of Stereotactic Radiosurgery in Her2+ brain mets
- Fatty Acid Synthase (FASN) as a Therapeutic Target for Breast Cancer Metastasis
- Video and audio from SABC 2009 (and more)
- ASCO (Dec. 2009) Reports
- HER2 expression occurs early in breast cancer dissemination
- Chloroquine + Her2 inhibitors = growth inhibition
- Breast cancer stem cells play a role in trastuzumab resistance in mouse models
- The topography of estrogen receptor expression in the human breast
- Leptin-induced breast cancer cell migration requires upregulation of survivin
- Cyclin D1 regulaties progesterone receptor expression
- Diabetes pharmacotherapy: A potential modifier of breast cancer prognosis?
- gene expression profiles reveals subtype-specific drug sensitivities among bc lines
- Body fat %, inflammation, and bc survival